Welcome to our dedicated page for Advanced Biomed SEC filings (Ticker: ADVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Advanced Biomed Inc.’s SEC reports read more like technical manuals than corporate updates. R&D line items, clinical study costs, and licensing royalties are scattered across hundreds of pages, leaving many investors asking, “How do I track Advanced Biomed Inc. insider trading Form 4 transactions?” or searching for the latest “Advanced Biomed Inc. quarterly earnings report 10-Q filing.” Stock Titan eliminates the hunt by streaming every disclosure the moment it hits EDGAR and indexing it by topic, segment, and form.
Our AI scans each 8-K, 10-K, and 10-Q, highlights material events, and produces plain-English summaries—so “Advanced Biomed Inc. SEC filings explained simply” is more than a promise. Need to spot fresh capital raises? The platform flags any Advanced Biomed Inc. 8-K material events explained. Curious about executive incentives? Drill straight into the proxy for “Advanced Biomed Inc. proxy statement executive compensation.” Real-time alerts surface “Advanced Biomed Inc. Form 4 insider transactions real-time,” while cross-links guide you to “Advanced Biomed Inc. annual report 10-K simplified” for historical context.
Whether you’re modeling revenue from a new flow-cytometry platform or monitoring pre-announcement trades, our tools turn disclosures into decisions. Compare R&D intensity quarter over quarter, review “Advanced Biomed Inc. earnings report filing analysis,” and stay ahead of “Advanced Biomed Inc. executive stock transactions Form 4.” In short, understanding Advanced Biomed Inc. SEC documents with AI means you spend less time parsing footnotes and more time acting on insight—all with complete coverage of every form, continuous updates, and expert context in a single, investor-focused hub.
Advanced Biomed Inc. (ADVB) reported a continued operating loss as it advances oncology diagnostics development. For the three months ended September 30, 2025, the company recorded a net loss of $386,901, wider than $265,580 a year earlier, driven mainly by higher research and development spending.
Total operating expenses were $523,914, including $235,992 for research and development and $287,922 for general and administrative costs. Other income, largely foreign exchange gains, added $137,013, partially offsetting expenses. There was no income tax expense.
As of September 30, 2025, Advanced Biomed held cash of $2,656,519 and total assets of $6,242,970, against total liabilities of $3,238,846 and stockholders’ equity of $3,004,124. Operating activities used $610,342 of cash in the quarter. Management discloses substantial doubt about the company’s ability to continue as a going concern but notes support from its March 2025 IPO, which raised $6.56 million in gross proceeds, and an equity line of credit allowing sales of up to $25,000,000 of common stock.
Advanced Biomed Inc. reported an annual 10-K describing a pre-commercial precision oncology business built on a proprietary microfluidic platform and ultra‑sensitive biosensor technology for circulating tumor cell (CTC) capture, identification and single‑cell isolation. The company has completed an Initial Public Offering of 1,640,000 shares at
The filing discloses a consolidated net loss of $3,258,969 for the year and net cash used in operating activities of $5,825,055. Management states these conditions give rise to substantial doubt about going concern, and the company intends to raise additional capital, rely on forthcoming operations, and seek financial support from related parties. The company holds multiple granted patents in China, the U.S., and international PCT filings covering its chips and separation technologies, and reports progress on mass‑production trials with injection molding partners.
FAQ
What is the current stock price of Advanced Biomed (ADVB)?
What is the market cap of Advanced Biomed (ADVB)?
